Precede Biosciences, shared a poster presentation at the ASCO annual meeting demonstrating accurate HER2 status detection across multiple cancers. 

179 samples from 172 patients with advanced breast, gastroesophageal, and ovarian cancers who had associated HER2 status scored from tissue-based IHC/ISH according to ASCO/CAP guidelines were selected. Precede Biosciences described the ability to classify HER2 status from 1 ml of plasma, using epigenomic signatures from a novel multi-analyte liquid biopsy platform, offering a minimally invasive approach for patient selection across cancers. 

Key Findings from ASCO 2024: 

• This retrospective study profiling 1ml plasma from 172 patients with advanced breast, gastroesophageal, and ovarian cancers demonstrates that HER2 classification using comprehensive epigenomic signals can be applied across multiple cancers. 

• This method may overcome variability due to tumor heterogeneity and inter-pathologist discordance. 

• A standardized approach across all solid tumors will enable harmonized patient selection for Trastuzumab deruxtecan. 

KOL insights

“There is a significant clinical need to understand target expression in cancers that can benefit from directed therapeutic modalities such as antibody-drug conjugates, radio conjugates, immuno-conjugates, and cell therapies” – Expert Opinion.

“The data presented at ASCO highlight the potential of a novel blood-based epigenomic liquid biopsy platform to simultaneously predict ER status and infer the activity of the ER signaling pathway in patients with metastatic breast cancer” – Expert Opinion.

Conclusion

With further development, the Precede Biosciences genome-wide profiling approach could alleviate clinical constraints associated with multiple tissue-based HER2 scoring assays (IHC/ISH) and enable longitudinal monitoring of HER2 status during therapy.